Top News: Last 7 Days
- Gilead’s CEO is remaking the biotech — and he’s looking for partners
- 23andMe cuts 100 jobs as demand for DNA tests drops
- Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron’s CBO hops ship to lead startup
- Gilead dusts off a failed Ebola drug as coronavirus spreads; Exelixis boasts positive Ph I/II data
- STAT Plus: This CEO wants to make telehealth more than ‘an exercise in convenience’
- STAT Plus: Pfizer’s big data exec on pharma’s ‘arms race’ to partner with companies like Fitbit, 23AndMe, and others
- STAT Plus: Verily’s top health leaders: We’re ‘trying to solve problems that many of us have lived’
- Tangible Science Announces Successful 2019 and Timing for Tangible Boost Launch
- Stanford researchers conduct census of cell surface proteins
- 23andMe laying off 14% of employees amid slump in DNA spit kit sales
See All News
Top Jobs: Last 30 Days
- Research Scientist – Anagenex – San Francisco, CA
- Scientist II, Protein Mass Spectrometry – Mitokinin, Inc – San Francisco, CA
- National Accounts Director, Federal & Strategic Partners – Exelixis Inc. – Alameda, CA
- Manufacturing Laboratory Technician (Consumable Cap-Coating) – Bio-Techne – San Jose, CA
- Research Associate/Scientist/Sr. Scientist – Bright Biologics LLC – Sunnyvale, CA
- Senior Manager of Fund and Investment Operations – Pilatus Capital – Emeryville, CA
- Research Associate – IgGenix, Inc. – San Francisco, CA
- Senior Financial Analyst – Exelixis Inc. – Alameda, CA
- Senior Financial Analyst – Exelixis Inc. – Alameda, CA
- Process Development Scientist, Downstream – Encoded Therapeutics – South San Francisco, CA
